DWP
LGND icon

Destiny Wealth Partners’s Ligand Pharmaceuticals LGND Stock Holding History

Destiny Wealth Partners’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-14
Closed -$1K – 559
2021
Q3 		$1K Buy
+14
New +$1.08K ﹤0.01% 505
2021
Q2 		– Sell
-14
Closed -$1K – 359
2021
Q1 		$1K Hold
14
– – ﹤0.01% 537
2020
Q4 		$1K Buy
+14
New +$798 ﹤0.01% 498

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Destiny Wealth Partners's LGND Position: Q4 2021 in Review

Destiny Wealth Partners sold out of Ligand Pharmaceuticals (LGND) in Q4 2021, closing a stake of 14 shares — an estimated $1K sold.

Destiny Wealth Partners first reported a position in LGND in Q4 2020 and held it in 3 quarters. The position peaked at $1K in Q3 2021. 221 funds tracked by Wall St. Rank hold LGND as of Q4 2021.

  • Destiny Wealth Partners reported no remaining Ligand Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Destiny Wealth Partners sold 14 Ligand Pharmaceuticals shares in Q4 2021, an estimated $1K.
  • Destiny Wealth Partners first reported a position in Ligand Pharmaceuticals in Q4 2020 and held it in 3 quarters.
  • Destiny Wealth Partners's Ligand Pharmaceuticals position peaked at $1K in Q3 2021.
  • 221 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2021.

Based on Destiny Wealth Partners's 13F filing for Q4 2021, filed 20 Jan 2022.